Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2026-05-30 Audit Report / Informat…
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026.
Audit Report / Information Classification · 85% confidence The document is titled “Annual Secretarial Compliance Report” prepared by an external firm of practising company secretaries and filed under Regulation 24A of SEBI’s Listing Obligations. It contains detailed audit-style tables, observations on statutory compliance and is a standalone compliance/audit report rather than a company Annual Report, earnings release or simple announcement. There is no financial statement data as in an interim or annual report, nor is it a brief notice. It best matches the “Audit Report / Information” category (AR). FY 2026
2026-05-30 English
Investor / Analysts call recording for the Quarter- 4 and Financial year ending March 31, 2026.
Regulatory Filings Classification · 87% confidence The document is an exchange filing under SEBI LODR Regulation 30 informing the exchanges and public about the availability of the audio recording of the Analysts/Investors Earnings Call via a link. It does not contain financial data or the call transcript itself but is a regulatory announcement required under listing rules. This falls into the general ‘Regulatory Filings’ category (RNS).
2026-05-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 78% confidence The document is a regulatory intimation to stock exchanges under SEBI LODR, providing a link to the audio recording of the analysts/investors earnings call. It does not include actual financial results or a transcript, nor is it the earnings release itself. It is a generic regulatory announcement of disclosure, fitting the ‘Regulatory Filings’ (RNS) category.
2026-05-26 English
Investor Presentation for Quarter- IV and Financial year ended on March 31, 2026.
Investor Presentation Classification · 93% confidence The document is a detailed slide deck titled “Investors Presentation – Quarter IV and Financial Year ended March 31, 2026” filed under SEBI Regulation 30. It contains financial charts, performance tables, strategy slides, and Safe Harbor language, characteristic of an investor presentation rather than a simple earnings release or regulatory notice. It is more substantive than a report publication announcement and clearly intended for investors.
2026-05-26 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is the full text of an investor presentation for Quarter IV and FY ended March 31, 2026, including Safe Harbor, strategy slides, financial performance tables and charts. It is not merely a publication notice but the substantive deck provided to investors. Therefore, it falls under the Investor Presentation category.
2026-05-26 English
Change in Auditors
Interim / Quarterly Report Classification · 85% confidence The document is an outcome of a Board Meeting under SEBI Listing Regulations, containing the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, complete with P&L, assets & liabilities, cash flow statements and auditor’s reports. It is not merely an earnings highlights release, nor a full annual report; rather it is a comprehensive financial filing of quarterly (and year-end) results. This aligns with our definition of an Interim / Quarterly Report (IR). FY 2026
2026-05-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.